155 related articles for article (PubMed ID: 2260855)
21. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
22. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies.
Nakase K; Tsuji K; Tamaki S; Tanigawa M; Ikeda T; Miyanishi E; Shiku H
Cancer Detect Prev; 2005; 29(3):256-9. PubMed ID: 15899555
[TBL] [Abstract][Full Text] [Related]
23. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
24. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Janiec K; Wajgt A; Kondera-Anasz Z
Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501
[TBL] [Abstract][Full Text] [Related]
25. [Relation between the clinical and cerebrospinal fluid parameters in multiple sclerosis, with special reference to subjects without oligoclonal IgG in the cerebrospinal fluid].
Poloni M; Rocchelli B; Mazzarello P; Delodovici M
Riv Neurol; 1981; 51(2):69-80. PubMed ID: 7244541
[TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
27. [Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation].
Lis AD; Brzezińska-Wcisło LA
Wiad Lek; 2003; 56(11-12):532-6. PubMed ID: 15058159
[TBL] [Abstract][Full Text] [Related]
28. CD4 T cell activation and disease activity at onset of multiple sclerosis.
Jensen J; Langkilde AR; Fenst C; Nicolaisen MS; Roed HG; Christiansen M; Sellebjerg F
J Neuroimmunol; 2004 Apr; 149(1-2):202-9. PubMed ID: 15020081
[TBL] [Abstract][Full Text] [Related]
29. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
Chowdhury SA; Lin J; Sadiq SA
Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
[TBL] [Abstract][Full Text] [Related]
30. Serum soluble interleukin-2 receptor in pancreatic cancer and chronic pancreatitis.
Pezzilli R; Billi P; Beltrandi E; Mancini R; Casadei-Maldini M; Casadei R; Greco VM; Campione O; Miglioli M
Ital J Gastroenterol; 1994 Apr; 26(3):137-40. PubMed ID: 8061340
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity.
Yosipovitch G; Shohat B; Bshara J; Wysenbeek A; Weinberger A
Isr J Med Sci; 1995 Jun; 31(6):345-8. PubMed ID: 7607852
[TBL] [Abstract][Full Text] [Related]
32. The relationship between levels of cerebrospinal fluid myelin basic protein and IgG measurements in patients with multiple sclerosis.
Warren KG; Catz I
Ann Neurol; 1985 May; 17(5):475-80. PubMed ID: 2408558
[TBL] [Abstract][Full Text] [Related]
33. [The level of soluble interleukin 2 receptor in esophageal carcinoma patients before and after radiotherapy].
Liu X; An H; Jiang Y
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):97-9. PubMed ID: 7656815
[TBL] [Abstract][Full Text] [Related]
34. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
35. The relationship of interleukin-2 and soluble interleukin-2 receptors to intrathecal immunoglobulin synthesis in patients with multiple sclerosis.
Sharief MK; Hentges R; Thompson EJ
J Neuroimmunol; 1991 Apr; 32(1):43-51. PubMed ID: 2002090
[TBL] [Abstract][Full Text] [Related]
36. Soluble IL-2 receptor in patients with primary nephrotic syndrome.
Ohno I; Gomi H; Matsuda H; Nakano H; Matsumoto H; Kodama K; Shibasaki T; Ishimoto F; Sakai O
Nihon Jinzo Gakkai Shi; 1991 May; 33(5):483-9. PubMed ID: 1895547
[TBL] [Abstract][Full Text] [Related]
37. Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility.
Peter JB; Boctor FN; Tourtellotte WW
Neurology; 1991 Jan; 41(1):121-3. PubMed ID: 1985276
[TBL] [Abstract][Full Text] [Related]
38. Soluble interleukin-2 receptor levels in cerebrospinal fluid of patients with acute lymphocytic leukemia or with non-Hodgkin's lymphoma.
Chang CS; Liu HW; Lin SF; Chen TP
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 May; 22(2):132-7. PubMed ID: 2605973
[TBL] [Abstract][Full Text] [Related]
39. [Multiple sclerosis--studies of the correlations between selected parameters of immune response and the clinical course of the disease].
Losy J; Michałowska-Wender G; Tokarz E; Wender M
Neurol Neurochir Pol; 1992; 26(2):164-71. PubMed ID: 1528374
[TBL] [Abstract][Full Text] [Related]
40. In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.
Sharief MK; Hentges R; Ciardi M; Thompson EJ
J Neurol; 1993 Jan; 240(1):46-50. PubMed ID: 8423463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
